{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T22:24:23Z","timestamp":1791671063682,"version":"4.3.4"},"reference-count":150,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,12,9]],"date-time":"2014-12-09T00:00:00Z","timestamp":1418083200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1007\/s10620-014-3473-z","type":"journal-article","created":{"date-parts":[[2014,12,8]],"date-time":"2014-12-08T13:50:56Z","timestamp":1418046656000},"page":"1528-1542","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Cell Mediators of Autoimmune Hepatitis and Their Therapeutic Implications"],"prefix":"10.1007","volume":"60","author":[{"given":"Aldo J.","family":"Montano-Loza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert J.","family":"Czaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,12,9]]},"reference":[{"key":"3473_CR1","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/hep.23584","volume":"51","author":"MP Manns","year":"2010","unstructured":"Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51:2193\u20132213.","journal-title":"Hepatology"},{"key":"3473_CR2","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1007\/s10620-014-3284-2","volume":"59","author":"AJ Czaja","year":"2014","unstructured":"Czaja AJ. Targeting apoptosis in autoimmune hepatitis. Dig Dis Sci. 2014;59:2890\u20132904.","journal-title":"Dig Dis Sci"},{"key":"3473_CR3","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1586\/17474124.1.1.113","volume":"1","author":"AJ Czaja","year":"2007","unstructured":"Czaja AJ. Autoimmune hepatitis. Part A: pathogenesis. Expert Rev Gastroenterol Hepatol. 2007;1:113\u2013128.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"3473_CR4","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/apt.12825","volume":"40","author":"AJ Czaja","year":"2014","unstructured":"Czaja AJ. Review article: chemokines as orchestrators of autoimmune hepatitis and potential therapeutic targets. Aliment Pharmacol Ther. 2014;40:261\u2013279.","journal-title":"Aliment Pharmacol Ther"},{"key":"3473_CR5","unstructured":"Marra F, Tacke F. Roles for chemokines in liver disease. Gastroenterology. 2014;147:577\u2013594, e571."},{"key":"3473_CR6","doi-asserted-by":"crossref","first-page":"857143","DOI":"10.1155\/2014\/857143","volume":"2014","author":"J Mbongue","year":"2014","unstructured":"Mbongue J, Nicholas D, Firek A, Langridge W. The role of dendritic cells in tissue-specific autoimmunity. J Immunol Res. 2014;2014:857143.","journal-title":"J Immunol Res"},{"key":"3473_CR7","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/ni1254","volume":"6","author":"LE Harrington","year":"2005","unstructured":"Harrington LE, Hatton RD, Mangan PR, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005;6:1123\u20131132.","journal-title":"Nat Immunol"},{"key":"3473_CR8","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jaut.2008.04.017","volume":"31","author":"V Dardalhon","year":"2008","unstructured":"Dardalhon V, Korn T, Kuchroo VK, Anderson AC. Role of Th1 and Th17 cells in organ-specific autoimmunity. J Autoimmun. 2008;31:252\u2013256.","journal-title":"J Autoimmun"},{"key":"3473_CR9","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1146\/annurev.immunol.021908.132710","volume":"27","author":"T Korn","year":"2009","unstructured":"Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol. 2009;27:485\u2013517.","journal-title":"Annu Rev Immunol"},{"key":"3473_CR10","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.0105-2896.2009.00887.x","volume":"234","author":"C Coquerelle","year":"2010","unstructured":"Coquerelle C, Moser M. DC subsets in positive and negative regulation of immunity. Immunol Rev. 2010;234:317\u2013334.","journal-title":"Immunol Rev"},{"key":"3473_CR11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/978-1-59745-395-0_2","volume":"380","author":"E Shklovskaya","year":"2007","unstructured":"Shklovskaya E, Fazekas de St Groth B. Balancing tolerance and immunity: the role of dendritic cell and T cell subsets. Methods Mol Biol. 2007;380:25\u201346.","journal-title":"Methods Mol Biol"},{"key":"3473_CR12","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1600-065X.2012.01146.x","volume":"249","author":"D Tang","year":"2012","unstructured":"Tang D, Kang R, Coyne CB, Zeh HJ, Lotze MT. PAMPs and DAMPs: signal 0s that spur autophagy and immunity. Immunol Rev. 2012;249:158\u2013175.","journal-title":"Immunol Rev"},{"key":"3473_CR13","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1182\/blood-2010-06-286393","volume":"118","author":"FX Hubert","year":"2011","unstructured":"Hubert FX, Kinkel SA, Davey GM, et al. Aire regulates the transfer of antigen from mTECs to dendritic cells for induction of thymic tolerance. Blood. 2011;118:2462\u20132472.","journal-title":"Blood"},{"key":"3473_CR14","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1128\/JVI.79.1.17-27.2005","volume":"79","author":"K McKenna","year":"2005","unstructured":"McKenna K, Beignon AS, Bhardwaj N. Plasmacytoid dendritic cells: linking innate and adaptive immunity. J Virol. 2005;79:17\u201327.","journal-title":"J Virol"},{"key":"3473_CR15","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.clim.2014.04.007","volume":"153","author":"VC Lombardi","year":"2014","unstructured":"Lombardi VC, Khaiboullina SF. Plasmacytoid dendritic cells of the gut: relevance to immunity and pathology. Clin Immunol. 2014;153:165\u2013177.","journal-title":"Clin Immunol"},{"key":"3473_CR16","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/ni1141","volume":"5","author":"M Colonna","year":"2004","unstructured":"Colonna M, Trinchieri G, Liu YJ. Plasmacytoid dendritic cells in immunity. Nat Immunol. 2004;5:1219\u20131226.","journal-title":"Nat Immunol"},{"key":"3473_CR17","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1146\/annurev.immunol.23.021704.115633","volume":"23","author":"YJ Liu","year":"2005","unstructured":"Liu YJ. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol. 2005;23:275\u2013306.","journal-title":"Annu Rev Immunol"},{"key":"3473_CR18","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1084\/jem.20061660","volume":"204","author":"T Ito","year":"2007","unstructured":"Ito T, Yang M, Wang YH, et al. Plasmacytoid dendritic cells prime IL-10-producing T regulatory cells by inducible costimulator ligand. J Exp Med. 2007;204:105\u2013115.","journal-title":"J Exp Med"},{"key":"3473_CR19","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nri3477","volume":"13","author":"D Ganguly","year":"2013","unstructured":"Ganguly D, Haak S, Sisirak V, Reizis B. The role of dendritic cells in autoimmunity. Nat Rev Immunol. 2013;13:566\u2013577.","journal-title":"Nat Rev Immunol"},{"key":"3473_CR20","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.clim.2005.08.010","volume":"117","author":"S Tamaki","year":"2005","unstructured":"Tamaki S, Homma S, Enomoto Y, et al. Autoimmune hepatic inflammation by vaccination of mice with dendritic cells loaded with well-differentiated hepatocellular carcinoma cells and administration of interleukin-12. Clin Immunol. 2005;117:280\u2013293.","journal-title":"Clin Immunol"},{"key":"3473_CR21","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/hep.27087","volume":"60","author":"A Ikeda","year":"2014","unstructured":"Ikeda A, Aoki N, Kido M, et al. Progression of autoimmune hepatitis is mediated by IL-18-producing dendritic cells and hepatic CXCL9 expression in mice. Hepatology. 2014;60:224\u2013236.","journal-title":"Hepatology"},{"key":"3473_CR22","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1189\/JLB.0309135","volume":"86","author":"B Gao","year":"2009","unstructured":"Gao B, Radaeva S, Park O. Liver natural killer and natural killer T cells: immunobiology and emerging roles in liver diseases. J Leukoc Biol. 2009;86:513\u2013528.","journal-title":"J Leukoc Biol"},{"key":"3473_CR23","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nri3065","volume":"11","author":"FD Shi","year":"2011","unstructured":"Shi FD, Ljunggren HG, La Cava A, Van Kaer L. Organ-specific features of natural killer cells. Nat Rev Immunol. 2011;11:658\u2013671.","journal-title":"Nat Rev Immunol"},{"key":"3473_CR24","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jaut.2013.07.003","volume":"46","author":"K Hudspeth","year":"2013","unstructured":"Hudspeth K, Pontarini E, Tentorio P, et al. The role of natural killer cells in autoimmune liver disease: a comprehensive review. J Autoimmun. 2013;46:55\u201365.","journal-title":"J Autoimmun"},{"key":"3473_CR25","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1126\/science.1198687","volume":"331","author":"E Vivier","year":"2011","unstructured":"Vivier E, Raulet DH, Moretta A, et al. Innate or adaptive immunity? The example of natural killer cells. Science. 2011;331:44\u201349.","journal-title":"Science"},{"key":"3473_CR26","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/hep.1840040529","volume":"4","author":"K Kaneda","year":"1984","unstructured":"Kaneda K, Kurioka N, Seki S, Wake K, Yamamoto S. Pit cell-hepatocyte contact in autoimmune hepatitis. Hepatology. 1984;4:955\u2013958.","journal-title":"Hepatology"},{"key":"3473_CR27","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/hep.24194","volume":"53","author":"S Shimoda","year":"2011","unstructured":"Shimoda S, Harada K, Niiro H, et al. Interaction between Toll-like receptors and natural killer cells in the destruction of bile ducts in primary biliary cirrhosis. Hepatology. 2011;53:1270\u20131281.","journal-title":"Hepatology"},{"key":"3473_CR28","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1002\/art.20216","volume":"50","author":"T Momot","year":"2004","unstructured":"Momot T, Koch S, Hunzelmann N, et al. Association of killer cell immunoglobulin-like receptors with scleroderma. Arthritis Rheum. 2004;50:1561\u20131565.","journal-title":"Arthritis Rheum"},{"key":"3473_CR29","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1084\/jem.193.10.1159","volume":"193","author":"JH Yen","year":"2001","unstructured":"Yen JH, Moore BE, Nakajima T, et al. Major histocompatibility complex class I-recognizing receptors are disease risk genes in rheumatoid arthritis. J Exp Med. 2001;193:1159\u20131167.","journal-title":"J Exp Med"},{"key":"3473_CR30","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1399-0039.2006.762_5.x","volume":"69","author":"AR Slik van der","year":"2007","unstructured":"van der Slik AR, Alizadeh BZ, Koeleman BP, Roep BO, Giphart MJ. Modelling KIR-HLA genotype disparities in type 1 diabetes. Tissue Antigens. 2007;69:101\u2013105.","journal-title":"Tissue Antigens"},{"key":"3473_CR31","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1084\/jem.182.3.875","volume":"182","author":"A Moretta","year":"1995","unstructured":"Moretta A, Sivori S, Vitale M, et al. Existence of both inhibitory (p58) and activatory (p50) receptors for HLA-C molecules in human natural killer cells. J Exp Med. 1995;182:875\u2013884.","journal-title":"J Exp Med"},{"key":"3473_CR32","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S1074-7613(00)80394-5","volume":"7","author":"M Uhrberg","year":"1997","unstructured":"Uhrberg M, Valiante NM, Shum BP, et al. Human diversity in killer cell inhibitory receptor genes. Immunity. 1997;7:753\u2013763.","journal-title":"Immunity"},{"key":"3473_CR33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2249.2007.03424.x","volume":"149","author":"RJ Boyton","year":"2007","unstructured":"Boyton RJ, Altmann DM. Natural killer cells, killer immunoglobulin-like receptors and human leucocyte antigen class I in disease. Clin Exp Immunol. 2007;149:1\u20138.","journal-title":"Clin Exp Immunol"},{"key":"3473_CR34","first-page":"121","volume":"298","author":"S Gonzalez","year":"2006","unstructured":"Gonzalez S, Groh V, Spies T. Immunobiology of human NKG2D and its ligands. Curr Top Microbiol Immunol. 2006;298:121\u2013138.","journal-title":"Curr Top Microbiol Immunol"},{"key":"3473_CR35","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1478-3231.2011.02608.x","volume":"32","author":"A Kahraman","year":"2012","unstructured":"Kahraman A, Fingas CD, Syn WK, Gerken G, Canbay A. Role of stress-induced NKG2D ligands in liver diseases. Liver international : official journal of the International Association for the Study of the liver.. 2012;32:370\u2013382.","journal-title":"Liver international : official journal of the International Association for the Study of the liver."},{"key":"3473_CR36","first-page":"2041","volume":"27","author":"S Holdenrieder","year":"2007","unstructured":"Holdenrieder S, Eichhorn P, Beuers U, et al. Soluble NKG2D ligands in hepatic autoimmune diseases and in benign diseases involved in marker metabolism. Anticancer Res. 2007;27:2041\u20132045.","journal-title":"Anticancer Res"},{"key":"3473_CR37","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1365-2893.2005.00543.x","volume":"12","author":"Y Chen","year":"2005","unstructured":"Chen Y, Wei H, Gao B, et al. Activation and function of hepatic NK cells in hepatitis B infection: an underinvestigated innate immune response. J Viral Hepat. 2005;12:38\u201345.","journal-title":"J Viral Hepat"},{"key":"3473_CR38","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jaut.2013.06.013","volume":"46","author":"PJ Trivedi","year":"2013","unstructured":"Trivedi PJ, Adams DH. Mucosal immunity in liver autoimmunity: a comprehensive review. J Autoimmun. 2013;46:97\u2013111.","journal-title":"J Autoimmun"},{"key":"3473_CR39","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.cgh.2007.12.048","volume":"6","author":"AJ Czaja","year":"2008","unstructured":"Czaja AJ. Genetic factors affecting the occurrence, clinical phenotype, and outcome of autoimmune hepatitis. Clin Gastroenterol Hepatol. 2008;6:379\u2013388.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3473_CR40","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/hep.1840120208","volume":"12","author":"A Lobo-Yeo","year":"1990","unstructured":"Lobo-Yeo A, Senaldi G, Portmann B, et al. Class I and class II major histocompatibility complex antigen expression on hepatocytes: a study in children with liver disease. Hepatology. 1990;12:224\u2013232.","journal-title":"Hepatology"},{"key":"3473_CR41","doi-asserted-by":"crossref","unstructured":"da Rocha Junior LF, Dantas AT, Duarte AL, et al. PPARgamma agonists in adaptive immunity: what do immune disorders and their models have to tell us? PPAR Res. 2013;2013:519724.","DOI":"10.1155\/2013\/519724"},{"key":"3473_CR42","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1182\/blood-2011-12-396101","volume":"119","author":"GT Tran","year":"2012","unstructured":"Tran GT, Hodgkinson SJ, Carter NM, et al. IL-5 promotes induction of antigen-specific CD4+ CD25+ T regulatory cells that suppress autoimmunity. Blood. 2012;119:4441\u20134450.","journal-title":"Blood"},{"key":"3473_CR43","doi-asserted-by":"crossref","first-page":"353","DOI":"10.4049\/jimmunol.150.2.353","volume":"150","author":"G Prete Del","year":"1993","unstructured":"Del Prete G, De Carli M, Almerigogna F, et al. Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J Immunol. 1993;150:353\u2013360.","journal-title":"J Immunol"},{"key":"3473_CR44","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/nature07036","volume":"453","author":"E Bettelli","year":"2008","unstructured":"Bettelli E, Korn T, Oukka M, Kuchroo VK. Induction and effector functions of T(H)17 cells. Nature. 2008;453:1051\u20131057.","journal-title":"Nature"},{"key":"3473_CR45","doi-asserted-by":"crossref","first-page":"e18909","DOI":"10.1371\/journal.pone.0018909","volume":"6","author":"L Zhao","year":"2011","unstructured":"Zhao L, Tang Y, You Z, et al. Interleukin-17 contributes to the pathogenesis of autoimmune hepatitis through inducing hepatic interleukin-6 expression. PLoS ONE. 2011;6:e18909.","journal-title":"PLoS ONE"},{"key":"3473_CR46","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.jhep.2012.07.008","volume":"57","author":"YH Oo","year":"2012","unstructured":"Oo YH, Banz V, Kavanagh D, et al. CXCR3-dependent recruitment and CCR6-mediated positioning of Th-17 cells in the inflamed liver. J Hepatol. 2012;57:1044\u20131051.","journal-title":"J Hepatol"},{"key":"3473_CR47","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/hep.23837","volume":"52","author":"SH Ki","year":"2010","unstructured":"Ki SH, Park O, Zheng M, et al. Interleukin-22 treatment ameliorates alcoholic liver injury in a murine model of chronic-binge ethanol feeding: role of signal transducer and activator of transcription 3. Hepatology. 2010;52:1291\u20131300.","journal-title":"Hepatology"},{"key":"3473_CR48","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature04753","volume":"441","author":"E Bettelli","year":"2006","unstructured":"Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006;441:235\u2013238.","journal-title":"Nature"},{"key":"3473_CR49","doi-asserted-by":"crossref","first-page":"236","DOI":"10.2741\/s148","volume":"3","author":"L Wu","year":"2011","unstructured":"Wu L, Van Kaer L. Natural killer T cells in health and disease. Front Biosci (Schol Ed). 2011;3:236\u2013251.","journal-title":"Front Biosci (Schol Ed)"},{"key":"3473_CR50","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nri2904","volume":"11","author":"SP Berzins","year":"2011","unstructured":"Berzins SP, Smyth MJ, Baxter AG. Presumed guilty: natural killer T cell defects and human disease. Nat Rev Immunol. 2011;11:131\u2013142.","journal-title":"Nat Rev Immunol"},{"key":"3473_CR51","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.2217\/imt.11.117","volume":"3","author":"JJ Subleski","year":"2011","unstructured":"Subleski JJ, Jiang Q, Weiss JM, Wiltrout RH. The split personality of NKT cells in malignancy, autoimmune and allergic disorders. Immunotherapy. 2011;3:1167\u20131184.","journal-title":"Immunotherapy"},{"key":"3473_CR52","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2217\/imt.10.85","volume":"3","author":"L Kaer Van","year":"2011","unstructured":"Van Kaer L, Parekh VV, Wu L. Invariant NK T cells: potential for immunotherapeutic targeting with glycolipid antigens. Immunotherapy. 2011;3:59\u201375.","journal-title":"Immunotherapy"},{"key":"3473_CR53","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1749-6632.2011.06380.x","volume":"1250","author":"S Zeissig","year":"2012","unstructured":"Zeissig S, Blumberg RS. Primary immunodeficiency associated with defects in CD1 and CD1-restricted T cells. Ann N Y Acad Sci. 2012;1250:14\u201324.","journal-title":"Ann N Y Acad Sci"},{"key":"3473_CR54","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.cyto.2010.11.001","volume":"53","author":"J Novak","year":"2011","unstructured":"Novak J, Lehuen A. Mechanism of regulation of autoimmunity by iNKT cells. Cytokine. 2011;53:263\u2013270.","journal-title":"Cytokine"},{"key":"3473_CR55","doi-asserted-by":"crossref","first-page":"5226","DOI":"10.4049\/jimmunol.1202909","volume":"190","author":"A Wehr","year":"2013","unstructured":"Wehr A, Baeck C, Heymann F, et al. Chemokine receptor CXCR6-dependent hepatic NK T Cell accumulation promotes inflammation and liver fibrosis. J Immunol. 2013;190:5226\u20135236.","journal-title":"J Immunol"},{"key":"3473_CR56","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/08830180601070195","volume":"26","author":"M Nowak","year":"2007","unstructured":"Nowak M, Stein-Streilein J. Invariant NKT cells and tolerance. Int Rev Immunol. 2007;26:95\u2013119.","journal-title":"Int Rev Immunol"},{"key":"3473_CR57","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1615\/CritRevImmunol.v26.i5.50","volume":"26","author":"G Dennert","year":"2006","unstructured":"Dennert G, Aswad F. The role of NKT cells in animal models of autoimmune hepatitis. Crit Rev Immunol. 2006;26:453\u2013473.","journal-title":"Crit Rev Immunol"},{"key":"3473_CR58","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.coi.2013.09.008","volume":"25","author":"J Mattner","year":"2013","unstructured":"Mattner J. Natural killer T (NKT) cells in autoimmune hepatitis. Curr Opin Immunol. 2013;25:697\u2013703.","journal-title":"Curr Opin Immunol"},{"key":"3473_CR59","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4291\/wjgp.v5.i2.107","volume":"5","author":"L Hammerich","year":"2014","unstructured":"Hammerich L, Tacke F. Role of gamma-delta T cells in liver inflammation and fibrosis. World J Gastrointest Pathophysiol. 2014;5:107\u2013113.","journal-title":"World J Gastrointest Pathophysiol"},{"key":"3473_CR60","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1159\/000086659","volume":"86","author":"W Holtmeier","year":"2005","unstructured":"Holtmeier W, Kabelitz D. Gammadelta T cells link innate and adaptive immune responses. Chem Immunol Allergy. 2005;86:151\u2013183.","journal-title":"Chem Immunol Allergy"},{"key":"3473_CR61","doi-asserted-by":"crossref","first-page":"5622","DOI":"10.4049\/jimmunol.0901772","volume":"183","author":"Y Wu","year":"2009","unstructured":"Wu Y, Wu W, Wong WM, et al. Human gamma delta T cells: a lymphoid lineage cell capable of professional phagocytosis. J Immunol. 2009;183:5622\u20135629.","journal-title":"J Immunol"},{"key":"3473_CR62","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s002810000042","volume":"22","author":"CT Morita","year":"2000","unstructured":"Morita CT, Mariuzza RA, Brenner MB. Antigen recognition by human gamma delta T cells: pattern recognition by the adaptive immune system. Springer Semin Immunopathol. 2000;22:191\u2013217.","journal-title":"Springer Semin Immunopathol"},{"key":"3473_CR63","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1002\/eji.200838354","volume":"38","author":"KA Rhodes","year":"2008","unstructured":"Rhodes KA, Andrew EM, Newton DJ, Tramonti D, Carding SR. A subset of IL-10-producing gammadelta T cells protect the liver from Listeria-elicited, CD8(+) T cell-mediated injury. Eur J Immunol. 2008;38:2274\u20132283.","journal-title":"Eur J Immunol"},{"key":"3473_CR64","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/hep.26697","volume":"59","author":"L Hammerich","year":"2014","unstructured":"Hammerich L, Bangen JM, Govaere O, et al. Chemokine receptor CCR6-dependent accumulation of gammadelta T cells in injured liver restricts hepatic inflammation and fibrosis. Hepatology. 2014;59:630\u2013642.","journal-title":"Hepatology"},{"key":"3473_CR65","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1365-2249.1992.tb06881.x","volume":"89","author":"L Wen","year":"1992","unstructured":"Wen L, Peakman M, Mieli-Vergani G, Vergani D. Elevation of activated gamma delta T cell receptor bearing T lymphocytes in patients with autoimmune chronic liver disease. Clin Exp Immunol. 1992;89:78\u201382.","journal-title":"Clin Exp Immunol"},{"key":"3473_CR66","first-page":"988","volume":"23","author":"EB Martins","year":"1996","unstructured":"Martins EB, Graham AK, Chapman RW, Fleming KA. Elevation of gamma delta T lymphocytes in peripheral blood and livers of patients with primary sclerosing cholangitis and other autoimmune liver diseases. Hepatology. 1996;23:988\u2013993.","journal-title":"Hepatology"},{"key":"3473_CR67","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/j.1600-0463.2009.02540.x","volume":"117","author":"HU Kasper","year":"2009","unstructured":"Kasper HU, Ligum D, Cucus J, et al. Liver distribution of gammadelta-T-cells in patients with chronic hepatitis of different etiology. APMIS.. 2009;117:779\u2013785.","journal-title":"APMIS."},{"key":"3473_CR68","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nri2781","volume":"10","author":"M Bonneville","year":"2010","unstructured":"Bonneville M, O\u2019Brien RL, Born WK. Gammadelta T cell effector functions: a blend of innate programming and acquired plasticity. Nat Rev Immunol. 2010;10:467\u2013478.","journal-title":"Nat Rev Immunol"},{"key":"3473_CR69","unstructured":"Rao R, Graffeo CS, Gulati R, et al. Interleukin 17-producing gammadeltaT cells promote hepatic regeneration in mice. Gastroenterology. 2014;147:473\u2013484, e472."},{"key":"3473_CR70","doi-asserted-by":"crossref","first-page":"4484","DOI":"10.4049\/jimmunol.176.7.4484","volume":"176","author":"MS Longhi","year":"2006","unstructured":"Longhi MS, Hussain MJ, Mitry RR, et al. Functional study of CD4+ CD25+ regulatory T cells in health and autoimmune hepatitis. J Immunol.. 2006;176:4484\u20134491.","journal-title":"J Immunol."},{"key":"3473_CR71","doi-asserted-by":"crossref","first-page":"46","DOI":"10.2307\/3346510","volume":"5","author":"BD Singer","year":"2014","unstructured":"Singer BD, King LS, D\u2019Alessio FR. Regulatory T cells as immunotherapy. Front Immunol. 2014;5:46.","journal-title":"Front Immunol"},{"key":"3473_CR72","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1126\/science.1079490","volume":"299","author":"S Hori","year":"2003","unstructured":"Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299:1057\u20131061.","journal-title":"Science"},{"key":"3473_CR73","doi-asserted-by":"crossref","first-page":"923","DOI":"10.4049\/jimmunol.172.2.923","volume":"172","author":"M Karim","year":"2004","unstructured":"Karim M, Kingsley CI, Bushell AR, Sawitzki BS, Wood KJ. Alloantigen-induced CD25+ CD4+ regulatory T cells can develop in vivo from CD25-CD4+ precursors in a thymus-independent process. J Immunol. 2004;172:923\u2013928.","journal-title":"J Immunol"},{"key":"3473_CR74","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/jmcb\/mjr039","volume":"4","author":"Q Lan","year":"2012","unstructured":"Lan Q, Fan H, Quesniaux V, et al. Induced Foxp3(+) regulatory T cells: a potential new weapon to treat autoimmune and inflammatory diseases? J Mol Cell Biol. 2012;4:22\u201328.","journal-title":"J Mol Cell Biol"},{"key":"3473_CR75","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/nature05479","volume":"445","author":"YY Wan","year":"2007","unstructured":"Wan YY, Flavell RA. Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression. Nature. 2007;445:766\u2013770.","journal-title":"Nature"},{"key":"3473_CR76","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.4049\/jimmunol.178.5.2940","volume":"178","author":"R Hontecillas","year":"2007","unstructured":"Hontecillas R, Bassaganya-Riera J. Peroxisome proliferator-activated receptor gamma is required for regulatory CD4+ T cell-mediated protection against colitis. J Immunol. 2007;178:2940\u20132949.","journal-title":"J Immunol"},{"key":"3473_CR77","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1053\/gast.2000.9365","volume":"119","author":"F Marra","year":"2000","unstructured":"Marra F, Efsen E, Romanelli RG, et al. Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology. 2000;119:466\u2013478.","journal-title":"Gastroenterology"},{"key":"3473_CR78","doi-asserted-by":"crossref","first-page":"996","DOI":"10.4049\/jimmunol.166.2.996","volume":"166","author":"S Sebastiani","year":"2001","unstructured":"Sebastiani S, Allavena P, Albanesi C, et al. Chemokine receptor expression and function in CD4+ T lymphocytes with regulatory activity. J Immunol. 2001;166:996\u20131002.","journal-title":"J Immunol"},{"key":"3473_CR79","doi-asserted-by":"crossref","first-page":"7602","DOI":"10.4049\/jimmunol.0901881","volume":"183","author":"JM Fletcher","year":"2009","unstructured":"Fletcher JM, Lonergan R, Costelloe L, et al. CD39+ Foxp3+ regulatory T Cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis. J Immunol. 2009;183:7602\u20137610.","journal-title":"J Immunol"},{"key":"3473_CR80","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/hep.26583","volume":"59","author":"CR Grant","year":"2014","unstructured":"Grant CR, Liberal R, Holder BS, et al. Dysfunctional CD39(POS) regulatory T cells and aberrant control of T-helper type 17 cells in autoimmune hepatitis. Hepatology. 2014;59:1007\u20131015.","journal-title":"Hepatology"},{"key":"3473_CR81","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1084\/jem.172.2.537","volume":"172","author":"S Sakaguchi","year":"1990","unstructured":"Sakaguchi S, Sakaguchi N. Thymus and autoimmunity: capacity of the normal thymus to produce pathogenic self-reactive T cells and conditions required for their induction of autoimmune disease. J Exp Med. 1990;172:537\u2013545.","journal-title":"J Exp Med"},{"key":"3473_CR82","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1093\/intimm\/dxf105","volume":"14","author":"H Bagavant","year":"2002","unstructured":"Bagavant H, Thompson C, Ohno K, Setiady Y, Tung KS. Differential effect of neonatal thymectomy on systemic and organ-specific autoimmune disease. Int Immunol. 2002;14:1397\u20131406.","journal-title":"Int Immunol"},{"key":"3473_CR83","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1053\/j.gastro.2008.06.042","volume":"135","author":"M Kido","year":"2008","unstructured":"Kido M, Watanabe N, Okazaki T, et al. Fatal autoimmune hepatitis induced by concurrent loss of naturally arising regulatory T cells and PD-1-mediated signaling. Gastroenterology. 2008;135:1333\u20131343.","journal-title":"Gastroenterology"},{"key":"3473_CR84","unstructured":"Aoki N, Kido M, Iwamoto S, et al. Dysregulated generation of follicular helper T cells in the spleen triggers fatal autoimmune hepatitis in mice. Gastroenterology. 2011;140:1322\u20131333, e1321\u2013e1325."},{"key":"3473_CR85","unstructured":"Maruoka R, Aoki N, Kido M, et al. Splenectomy prolongs the effects of corticosteroids in mouse models of autoimmune hepatitis. Gastroenterology. 2013;145:209\u2013220, e209."},{"key":"3473_CR86","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1182\/blood-2006-12-064527","volume":"110","author":"G Borsellino","year":"2007","unstructured":"Borsellino G, Kleinewietfeld M, Di Mitri D, et al. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood. 2007;110:1225\u20131232.","journal-title":"Blood"},{"key":"3473_CR87","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1084\/jem.20062512","volume":"204","author":"S Deaglio","year":"2007","unstructured":"Deaglio S, Dwyer KM, Gao W, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med. 2007;204:1257\u20131265.","journal-title":"J Exp Med"},{"key":"3473_CR88","doi-asserted-by":"crossref","first-page":"6780","DOI":"10.4049\/jimmunol.177.10.6780","volume":"177","author":"JJ Kobie","year":"2006","unstructured":"Kobie JJ, Shah PR, Yang L, et al. T regulatory and primed uncommitted CD4 T cells express CD73, which suppresses effector CD4 T cells by converting 5\u2019-adenosine monophosphate to adenosine. J Immunol. 2006;177:6780\u20136786.","journal-title":"J Immunol"},{"key":"3473_CR89","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/hep.25682","volume":"56","author":"R Liberal","year":"2012","unstructured":"Liberal R, Grant CR, Holder BS, et al. The impaired immune regulation of autoimmune hepatitis is linked to a defective galectin-9\/tim-3 pathway. Hepatology. 2012;56:677\u2013686.","journal-title":"Hepatology"},{"key":"3473_CR90","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1600-065X.2009.00772.x","volume":"229","author":"R Rodriguez-Manzanet","year":"2009","unstructured":"Rodriguez-Manzanet R, DeKruyff R, Kuchroo VK, Umetsu DT. The costimulatory role of TIM molecules. Immunol Rev. 2009;229:259\u2013270.","journal-title":"Immunol Rev"},{"key":"3473_CR91","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1055\/s-0030-1255351","volume":"30","author":"HE Wasmuth","year":"2010","unstructured":"Wasmuth HE, Tacke F, Trautwein C. Chemokines in liver inflammation and fibrosis. Sem Liver Dis. 2010;30:215\u2013225.","journal-title":"Sem Liver Dis"},{"key":"3473_CR92","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.autrev.2008.12.002","volume":"8","author":"EY Lee","year":"2009","unstructured":"Lee EY, Lee ZH, Song YW. CXCL10 and autoimmune diseases. Autoimmun Rev. 2009;8:379\u2013383.","journal-title":"Autoimmun Rev"},{"key":"3473_CR93","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.autrev.2013.10.010","volume":"13","author":"A Antonelli","year":"2014","unstructured":"Antonelli A, Ferrari SM, Giuggioli D, et al. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. Autoimmun Rev. 2014;13:272\u2013280.","journal-title":"Autoimmun Rev"},{"key":"3473_CR94","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1089\/jir.2013.0075","volume":"34","author":"A Landi","year":"2014","unstructured":"Landi A, Weismuller TJ, Lankisch TO, et al. Differential serum levels of eosinophilic eotaxins in primary sclerosing cholangitis, primary biliary cirrhosis, and autoimmune hepatitis. J Interferon Cytokine Res. 2014;34:204\u2013214.","journal-title":"J Interferon Cytokine Res"},{"key":"3473_CR95","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1111\/j.1582-4934.2009.00787.x","volume":"13","author":"K Bourd-Boittin","year":"2009","unstructured":"Bourd-Boittin K, Basset L, Bonnier D, et al. CX3CL1\/fractalkine shedding by human hepatic stellate cells: contribution to chronic inflammation in the liver. J Cell Mol Med. 2009;13:1526\u20131535.","journal-title":"J Cell Mol Med"},{"key":"3473_CR96","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/hep.23318","volume":"51","author":"S Shimoda","year":"2010","unstructured":"Shimoda S, Harada K, Niiro H, et al. CX3CL1 (fractalkine): a signpost for biliary inflammation in primary biliary cirrhosis. Hepatology. 2010;51:567\u2013575.","journal-title":"Hepatology"},{"key":"3473_CR97","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1002\/hep.23894","volume":"52","author":"KR Karlmark","year":"2010","unstructured":"Karlmark KR, Zimmermann HW, Roderburg C, et al. The fractalkine receptor CX(3)CR1 protects against liver fibrosis by controlling differentiation and survival of infiltrating hepatic monocytes. Hepatology. 2010;52:1769\u20131782.","journal-title":"Hepatology"},{"key":"3473_CR98","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/hep.23795","volume":"52","author":"T Aoyama","year":"2010","unstructured":"Aoyama T, Inokuchi S, Brenner DA, Seki E. CX3CL1-CX3CR1 interaction prevents carbon tetrachloride-induced liver inflammation and fibrosis in mice. Hepatology. 2010;52:1390\u20131400.","journal-title":"Hepatology"},{"key":"3473_CR99","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1161\/ATVBAHA.111.237412","volume":"32","author":"GE White","year":"2012","unstructured":"White GE, Greaves DR. Fractalkine: a survivor\u2019s guide: chemokines as antiapoptotic mediators. Arterioscler Thromb Vasc Biol. 2012;32:589\u2013594.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"3473_CR100","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jhep.2004.03.008","volume":"41","author":"MS Longhi","year":"2004","unstructured":"Longhi MS, Ma Y, Bogdanos DP, et al. Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease. J Hepatol. 2004;41:31\u201337.","journal-title":"J Hepatol"},{"key":"3473_CR101","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jhep.2012.02.029","volume":"57","author":"M Peiseler","year":"2012","unstructured":"Peiseler M, Sebode M, Franke B, et al. FOXP3+ regulatory T cells in autoimmune hepatitis are fully functional and not reduced in frequency. J Hepatol. 2012;57:125\u2013132.","journal-title":"J Hepatol"},{"key":"3473_CR102","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jaut.2005.05.001","volume":"25","author":"MS Longhi","year":"2005","unstructured":"Longhi MS, Ma Y, Mitry RR, et al. Effect of CD4+ CD25+ regulatory T-cells on CD8 T-cell function in patients with autoimmune hepatitis. J Autoimmun. 2005;25:63\u201371.","journal-title":"J Autoimmun"},{"key":"3473_CR103","doi-asserted-by":"crossref","unstructured":"Holder BS, Grant CR, Liberal R, et al. Retinoic acid stabilizes antigen-specific regulatory T-cell function in autoimmune hepatitis type 2. J Autoimmun. 2014;53:26\u201332.","DOI":"10.1016\/j.jaut.2014.02.001"},{"key":"3473_CR104","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/hep.24039","volume":"53","author":"MS Longhi","year":"2011","unstructured":"Longhi MS, Hussain MJ, Kwok WW, et al. Autoantigen-specific regulatory T cells, a potential tool for immune-tolerance reconstitution in type-2 autoimmune hepatitis. Hepatology. 2011;53:536\u2013547.","journal-title":"Hepatology"},{"key":"3473_CR105","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/hep.26023","volume":"57","author":"P Lapierre","year":"2013","unstructured":"Lapierre P, Beland K, Yang R, Alvarez F. Adoptive transfer of ex vivo expanded regulatory T cells in an autoimmune hepatitis murine model restores peripheral tolerance. Hepatology. 2013;57:217\u2013227.","journal-title":"Hepatology"},{"key":"3473_CR106","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.4049\/jimmunol.167.4.1945","volume":"167","author":"S Gregori","year":"2001","unstructured":"Gregori S, Casorati M, Amuchastegui S, et al. Regulatory T cells induced by 1 alpha,25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance. J Immunol. 2001;167:1945\u20131953.","journal-title":"J Immunol"},{"key":"3473_CR107","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.trim.2007.05.005","volume":"18","author":"DG Lim","year":"2007","unstructured":"Lim DG, Joe IY, Park YH, et al. Effect of immunosuppressants on the expansion and function of naturally occurring regulatory T cells. Transpl Immunol. 2007;18:94\u2013100.","journal-title":"Transpl Immunol"},{"key":"3473_CR108","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1016\/j.transproceed.2012.09.091","volume":"44","author":"C Miroux","year":"2012","unstructured":"Miroux C, Morales O, Ouaguia L, et al. Corticosteroids do not reverse the inhibitory effect of cyclosporine on regulatory T-cell activity in contrast to mycophenolate mofetil. Transpl Proc. 2012;44:2834\u20132839.","journal-title":"Transpl Proc"},{"key":"3473_CR109","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.4049\/jimmunol.165.5.2374","volume":"165","author":"A Mehling","year":"2000","unstructured":"Mehling A, Grabbe S, Voskort M, et al. Mycophenolate mofetil impairs the maturation and function of murine dendritic cells. J Immunol. 2000;165:2374\u20132381.","journal-title":"J Immunol"},{"key":"3473_CR110","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.trim.2012.05.001","volume":"27","author":"T Wu","year":"2012","unstructured":"Wu T, Zhang L, Xu K, et al. Immunosuppressive drugs on inducing Ag-specific CD4(+)CD25(+)Foxp3(+) Treg cells during immune response in vivo. Transpl Immunol. 2012;27:30\u201338.","journal-title":"Transpl Immunol"},{"key":"3473_CR111","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1017\/S0029665111003193","volume":"71","author":"MT Cantorna","year":"2012","unstructured":"Cantorna MT, Zhao J, Yang L. Vitamin D, invariant natural killer T-cells and experimental autoimmune disease. Proc Nutr Soc. 2012;71:62\u201366.","journal-title":"Proc Nutr Soc"},{"key":"3473_CR112","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1007\/s10620-014-3267-3","volume":"59","author":"C Efe","year":"2014","unstructured":"Efe C, Kav T, Aydin C, et al. Low serum vitamin D levels are associated with severe histological features and poor response to therapy in patients with autoimmune hepatitis. Dig Dis Sci. 2014;59:3035\u20133042.","journal-title":"Dig Dis Sci"},{"key":"3473_CR113","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1053\/jhep.2002.30084","volume":"35","author":"A Vogel","year":"2002","unstructured":"Vogel A, Strassburg CP, Manns MP. Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune hepatitis. Hepatology. 2002;35:126\u2013131.","journal-title":"Hepatology"},{"key":"3473_CR114","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1440-1746.2005.03532.x","volume":"20","author":"L Fan","year":"2005","unstructured":"Fan L, Tu X, Zhu Y, et al. Genetic association of vitamin D receptor polymorphisms with autoimmune hepatitis and primary biliary cirrhosis in the Chinese. J Gastroenterol Hepatol. 2005;20:249\u2013255.","journal-title":"J Gastroenterol Hepatol"},{"key":"3473_CR115","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.clinre.2013.05.016","volume":"37","author":"DS Smyk","year":"2013","unstructured":"Smyk DS, Orfanidou T, Invernizzi P, Bogdanos DP, Lenzi M. Vitamin D in autoimmune liver disease. Clin Res Hepatol Gastroenterol. 2013;37:535\u2013545.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"3473_CR116","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/hep.22071","volume":"47","author":"MS Longhi","year":"2008","unstructured":"Longhi MS, Meda F, Wang P, et al. Expansion and de novo generation of potentially therapeutic regulatory T cells in patients with autoimmune hepatitis. Hepatology. 2008;47:581\u2013591.","journal-title":"Hepatology"},{"key":"3473_CR117","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1053\/j.gastro.2012.02.041","volume":"142","author":"MS Longhi","year":"2012","unstructured":"Longhi MS, Liberal R, Holder B, et al. Inhibition of interleukin-17 promotes differentiation of CD25(-) cells into stable T regulatory cells in patients with autoimmune hepatitis. Gastroenterology. 2012;142:1526\u20131535.","journal-title":"Gastroenterology"},{"key":"3473_CR118","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.immuni.2009.09.006","volume":"31","author":"C Penaranda","year":"2009","unstructured":"Penaranda C, Bluestone JA. Is antigen specificity of autoreactive T cells the key to islet entry? Immunity. 2009;31:534\u2013536.","journal-title":"Immunity"},{"key":"3473_CR119","doi-asserted-by":"crossref","unstructured":"Sagoo P, Ali N, Garg G, et al. Human regulatory T cells with alloantigen specificity are more potent inhibitors of alloimmune skin graft damage than polyclonal regulatory T cells. Sci Transl Med. 2011;3:83ra42.","DOI":"10.1126\/scitranslmed.3002076"},{"key":"3473_CR120","doi-asserted-by":"crossref","first-page":"19078","DOI":"10.1073\/pnas.0907396106","volume":"106","author":"GP Wright","year":"2009","unstructured":"Wright GP, Notley CA, Xue SA, et al. Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritis. Proc Natl Acad Sci USA. 2009;106:19078\u201319083.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3473_CR121","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/gt.2009.75","volume":"16","author":"AA Hombach","year":"2009","unstructured":"Hombach AA, Kofler D, Rappl G, Abken H. Redirecting human CD4+ CD25+ regulatory T cells from the peripheral blood with pre-defined target specificity. Gene Ther. 2009;16:1088\u20131096.","journal-title":"Gene Ther"},{"key":"3473_CR122","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.clim.2013.11.004","volume":"150","author":"H Jethwa","year":"2014","unstructured":"Jethwa H, Adami AA, Maher J. Use of gene-modified regulatory T-cells to control autoimmune and alloimmune pathology: is now the right time? Clin Immunol. 2014;150:51\u201363.","journal-title":"Clin Immunol"},{"key":"3473_CR123","first-page":"278093","volume":"2012","author":"J Maher","year":"2012","unstructured":"Maher J. Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells. ISRN Oncol.. 2012;2012:278093.","journal-title":"ISRN Oncol."},{"key":"3473_CR124","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/nrc2355","volume":"8","author":"SA Rosenberg","year":"2008","unstructured":"Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008;8:299\u2013308.","journal-title":"Nat Rev Cancer"},{"key":"3473_CR125","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2174\/187152812803250980","volume":"11","author":"AJ Czaja","year":"2012","unstructured":"Czaja AJ. Nonstandard drugs and feasible new interventions for autoimmune hepatitis. Part-II. Inflamm Allergy Drug Targets. 2012;11:351\u2013363.","journal-title":"Inflamm Allergy Drug Targets"},{"key":"3473_CR126","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jns.2008.07.027","volume":"274","author":"H Ochi","year":"2008","unstructured":"Ochi H, Abraham M, Ishikawa H, et al. New immunosuppressive approaches: oral administration of CD3-specific antibody to treat autoimmunity. J Neurol Sci. 2008;274:9\u201312.","journal-title":"J Neurol Sci"},{"key":"3473_CR127","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/nm1749","volume":"14","author":"S Perruche","year":"2008","unstructured":"Perruche S, Zhang P, Liu Y, et al. CD3-specific antibody-induced immune tolerance involves transforming growth factor-beta from phagocytes digesting apoptotic T cells. Nat Med. 2008;14:528\u2013535.","journal-title":"Nat Med"},{"key":"3473_CR128","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.2337\/db06-1632","volume":"56","author":"H Ishikawa","year":"2007","unstructured":"Ishikawa H, Ochi H, Chen ML, et al. Inhibition of autoimmune diabetes by oral administration of anti-CD3 monoclonal antibody. Diabetes. 2007;56:2103\u20132109.","journal-title":"Diabetes"},{"key":"3473_CR129","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1056\/NEJMoa012864","volume":"346","author":"KC Herold","year":"2002","unstructured":"Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med. 2002;346:1692\u20131698.","journal-title":"N Engl J Med"},{"key":"3473_CR130","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1053\/j.seminhematol.2010.01.011","volume":"47","author":"GJ Weiner","year":"2010","unstructured":"Weiner GJ. Rituximab: mechanism of action. Semin Hematol. 2010;47:115\u2013123.","journal-title":"Semin Hematol"},{"key":"3473_CR131","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1478-3231.2006.01262.x","volume":"26","author":"ES Santos","year":"2006","unstructured":"Santos ES, Arosemena LR, Raez LE, O\u2019Brien C, Regev A. Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: case report and review of literature. Liver Int. 2006;26:625\u2013629.","journal-title":"Liver Int"},{"key":"3473_CR132","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1097\/MCG.0b013e3180f60b7a","volume":"42","author":"JT Evans","year":"2008","unstructured":"Evans JT, Shepard MM, Oates JC, Self SE, Reuben A. Rituximab-responsive cryoglobulinemic glomerulonephritis in a patient with autoimmune hepatitis. J Clin Gastroenterol. 2008;42:862\u2013863.","journal-title":"J Clin Gastroenterol"},{"key":"3473_CR133","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1159\/000322693","volume":"4","author":"E Barth","year":"2010","unstructured":"Barth E, Clawson J. A Case of Autoimmune Hepatitis Treated with Rituximab. Case Rep Gastroenterol. 2010;4:502\u2013509.","journal-title":"Case Rep Gastroenterol"},{"key":"3473_CR134","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.4067\/S0034-98872011001100015","volume":"139","author":"EJ Carey","year":"2011","unstructured":"Carey EJ, Somaratne K, Rakela J. Successful rituximab therapy in refractory autoimmune hepatitis and Evans syndrome. Rev Med Chil. 2011;139:1484\u20131487.","journal-title":"Rev Med Chil"},{"key":"3473_CR135","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1155\/2013\/512624","volume":"27","author":"KW Burak","year":"2013","unstructured":"Burak KW, Swain MG, Santodomino-Garzon T, et al. Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy. Can J Gastroenterol. 2013;27:273\u2013280.","journal-title":"Can J Gastroenterol"},{"key":"3473_CR136","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s10875-011-9590-y","volume":"32","author":"JQ Yang","year":"2012","unstructured":"Yang JQ, Kim PJ, Singh RR. Brief treatment with iNKT cell ligand alpha-galactosylceramide confers a long-term protection against lupus. J Clin Immunol. 2012;32:106\u2013113.","journal-title":"J Clin Immunol"},{"key":"3473_CR137","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1365-2249.2011.04454.x","volume":"166","author":"HJ Blumenfeld","year":"2011","unstructured":"Blumenfeld HJ, Tohn R, Haeryfar SM, et al. Structure-guided design of an invariant natural killer T cell agonist for optimum protection from type 1 diabetes in non-obese diabetic mice. Clin Exp Immunol. 2011;166:121\u2013133.","journal-title":"Clin Exp Immunol"},{"key":"3473_CR138","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2249.2011.04369.x","volume":"164","author":"Y Yoshiga","year":"2011","unstructured":"Yoshiga Y, Goto D, Segawa S, et al. Activation of natural killer T cells by alpha-carba-GalCer (RCAI-56), a novel synthetic glycolipid ligand, suppresses murine collagen-induced arthritis. Clin Exp Immunol. 2011;164:236\u2013247.","journal-title":"Clin Exp Immunol"},{"key":"3473_CR139","doi-asserted-by":"crossref","first-page":"69","DOI":"10.4161\/mabs.4.1.18713","volume":"4","author":"MF Maurer","year":"2012","unstructured":"Maurer MF, Garrigues U, Jaspers SR, et al. Generation and characterization of human anti-human IL-21 neutralizing monoclonal antibodies. MAbs.. 2012;4:69\u201383.","journal-title":"MAbs."},{"key":"3473_CR140","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.2337\/dc11-0472","volume":"34","author":"N Giannoukakis","year":"2011","unstructured":"Giannoukakis N, Phillips B, Finegold D, Harnaha J, Trucco M. Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients. Diabetes Care. 2011;34:2026\u20132032.","journal-title":"Diabetes Care"},{"key":"3473_CR141","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1002\/eji.1830251016","volume":"25","author":"M Moser","year":"1995","unstructured":"Moser M, De Smedt T, Sornasse T, et al. Glucocorticoids down-regulate dendritic cell function in vitro and in vivo. Eur J Immunol. 1995;25:2818\u20132824.","journal-title":"Eur J Immunol"},{"key":"3473_CR142","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1016\/j.transproceed.2003.09.020","volume":"35","author":"D Sauma","year":"2003","unstructured":"Sauma D, Fierro A, Mora JR, et al. Cyclosporine preconditions dendritic cells during differentiation and reduces IL-2 and IL-12 production following activation: a potential tolerogenic effect. Transplant Proc. 2003;35:2515\u20132517.","journal-title":"Transplant Proc"},{"key":"3473_CR143","doi-asserted-by":"crossref","unstructured":"Fischer R, Turnquist HR, Taner T, Thomson AW. Use of rapamycin in the induction of tolerogenic dendritic cells. Handb Exp Pharmacol. 2009;188:215\u2013232.","DOI":"10.1007\/978-3-540-71029-5_10"},{"key":"3473_CR144","doi-asserted-by":"crossref","first-page":"e45185","DOI":"10.1371\/journal.pone.0045185","volume":"7","author":"TS Lim","year":"2012","unstructured":"Lim TS, Goh JK, Mortellaro A, et al. CD80 and CD86 differentially regulate mechanical interactions of T-cells with antigen-presenting dendritic cells and B-cells. PLoS ONE. 2012;7:e45185.","journal-title":"PLoS ONE"},{"key":"3473_CR145","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1126\/science.284.5415.770","volume":"284","author":"S Artavanis-Tsakonas","year":"1999","unstructured":"Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science. 1999;284:770\u2013776.","journal-title":"Science"},{"key":"3473_CR146","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1007\/s00125-012-2723-x","volume":"55","author":"DH Kim","year":"2012","unstructured":"Kim DH, Lee JC, Lee MK, Kim KW, Lee MS. Treatment of autoimmune diabetes in NOD mice by Toll-like receptor 2 tolerance in conjunction with dipeptidyl peptidase 4 inhibition. Diabetologia. 2012;55:3308\u20133317.","journal-title":"Diabetologia"},{"key":"3473_CR147","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1038\/sj.gt.3301513","volume":"8","author":"PT Coates","year":"2001","unstructured":"Coates PT, Krishnan R, Kireta S, Johnston J, Russ GR. Human myeloid dendritic cells transduced with an adenoviral interleukin-10 gene construct inhibit human skin graft rejection in humanized NOD-scid chimeric mice. Gene Ther. 2001;8:1224\u20131233.","journal-title":"Gene Ther"},{"key":"3473_CR148","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.4049\/jimmunol.173.7.4331","volume":"173","author":"J Machen","year":"2004","unstructured":"Machen J, Harnaha J, Lakomy R, et al. Antisense oligonucleotides down-regulating costimulation confer diabetes-preventive properties to nonobese diabetic mouse dendritic cells. J Immunol. 2004;173:4331\u20134341.","journal-title":"J Immunol"},{"key":"3473_CR149","doi-asserted-by":"crossref","first-page":"8451","DOI":"10.1016\/j.vaccine.2011.07.077","volume":"29","author":"O Odumosu","year":"2011","unstructured":"Odumosu O, Nicholas D, Payne K, Langridge W. Cholera toxin B subunit linked to glutamic acid decarboxylase suppresses dendritic cell maturation and function. Vaccine. 2011;29:8451\u20138458.","journal-title":"Vaccine"},{"key":"3473_CR150","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.intimp.2013.08.018","volume":"17","author":"WS Lee","year":"2013","unstructured":"Lee WS, Lee SM, Kim MK, et al. The tryptophan metabolite 3-hydroxyanthranilic acid suppresses T cell responses by inhibiting dendritic cell activation. Int Immunopharmacol. 2013;17:721\u2013726.","journal-title":"Int Immunopharmacol"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-014-3473-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-014-3473-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-014-3473-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T18:05:37Z","timestamp":1717610737000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-014-3473-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,9]]},"references-count":150,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["3473"],"URL":"https:\/\/doi.org\/10.1007\/s10620-014-3473-z","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,9]]}}}